18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer
Reason given: \<75% participation
Key facts
- Where
- Houston, United StatesSee the site
Where in United States
- M D Anderson Cancer CenterHouston, United StatesNo longer taking part
Trial details
- Who runs it
- M.D. Anderson Cancer Center
- Trial code
- NCT06549413
- Record updated
- 13 August 2026
- Original description
This study is being done to learn how 18F-FSPG PET/CT scan results may be related to the response to chemotherapy and radiation in patients with esophageal cancer.Read full original descriptionShow less
This study is being done to learn how 18F-FSPG PET/CT scan results may be related to the response to chemotherapy and radiation in patients with esophageal cancer.
Inclusion: * ≥ 18 years of age; Patients with locally advanced esophageal cancer; Patients with untreated documented carcinoma of the esophagus that is > 2 cm who are going to receive systemic therapy concurrently with radiation as primary therapy; Ability to provide written informed consent in accordance with institutional policies; Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 1 week of the proposed investigational PET/CT scan(s) prior to injection of the investigational radiopharmaceutical.
Exclusion: * Body weight ≥ 400 pounds or body habitus or disability that will not permit the imaging protocol to be performed; Pregnant or lactating females; Have an allergy to intravenous contrast; eGFR < 30.